文献速递心力衰竭与心肌病心律失常

CAR-T细胞治疗晚期恶性肿瘤的心脏毒性

Cardiotoxicity from chimeric antigen receptor-T cell therapy for advanced malignancies.
PubMed 文献 · Eur Heart J · 2022-01-01

本文综述了CAR-T细胞治疗晚期恶性肿瘤相关的心血管风险,重点讨论细胞因子释放综合征(CRS)与心血管事件的关联,包括窦性心动过速、低血压、QT间期延长、快速性心律失常、心肌缺血、静脉血栓栓塞及心功能不全至心力衰竭和心源性休克,并总结发生率、特征、治疗选择及整合管理流程。

要点

  • CRS是CAR-T治疗后心血管不良事件的重要驱动因素。
  • 常见心血管表现包括窦性心动过速、低血压、QTc延长和快速性心律失常。
  • 需监测心肌缺血、静脉血栓栓塞及心功能不全至心力衰竭或心源性休克。

核心结论

  • CAR-T细胞治疗可引发CRS相关的心血管不良事件,需心内科医生关注并纳入整合管理。

研究设计与样本

  • 综述,讨论CAR-T细胞治疗相关心血管风险的发生率、特征和治疗选择。

主要发现

  • CRS严重程度从轻度流感样症状到伴多器官衰竭和高死亡风险的暴发性高炎症状态不等。
  • 窦性心动过速和低血压是CRS最常见的心血管表现。
  • 校正QT间期延长和快速性心律失常(包括室性心律失常和心房颤动)与CRS密切关联。
  • CAR-T治疗期间可诱发心肌缺血和静脉血栓栓塞事件。
  • 可观察到心功能变化直至心力衰竭和心源性休克,严重瓣膜性心脏病患者在CRS背景下也可能出现。

临床怎么用

  • 心内科医生应了解CAR-T治疗的心血管风险,参与监测和管理CRS相关心血管事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chimeric antigen receptor (CAR)-T cell therapy is the next revolutionary advance in cancer therapy. By using ex vivo engineered T cells to specifically target antigens, a targeted immune reaction is induced. Chimeric antigen receptor-T cell therapy is approved for patients suffering from advanced and refractory B cell and plasma cell malignancies and is undergoing testing for various other haematologic and solid malignancies. In the process of triggering an anticancer immune reaction, a systemic inflammatory response can emerge as cytokine release syndrome (CRS). The severity of CRS is highly variable across patients, ranging from mild flu-like symptoms to fulminant hyperinflammatory states with excessive immune activation, associated multiorgan failure and high mortality risk. Cytokine release syndrome is also an important factor for adverse cardiovascular (CV) events. Sinus tachycardia and hypotension are the most common reflections, similar to what is seen with other systemic inflammatory response syndromes. Corrected QT interval prolongation and tachyarrhythmias, including ventricular arrhythmias and atrial fibrillation, also show a close link with CRS. Events of myocardial ischaemia and venous thromboembolism can be provoked during CAR-T cell therapy. Although not as closely related to CRS, changes in cardiac function can be observed to the point of heart failure and cardiogenic shock. This may also be encountered in patients with severe valvular heart disease in the setting of CRS. This review will discuss the pertinent CV risks of the growing field of CAR-T cell therapy for today's cardiologists, including incidence, characteristics, and treatment options, and will conclude with an integrated management algorithm.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Totzeck, Michel, Lin, et al. Cardiotoxicity from chimeric antigen receptor-T cell therapy for advanced malignancies. Eur Heart J. 2022. PMID: 35257157. doi:10.1093/eurheartj/ehac106

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。